{"id":870052,"date":"2025-07-15T18:12:19","date_gmt":"2025-07-15T22:12:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/"},"modified":"2025-07-15T18:12:19","modified_gmt":"2025-07-15T22:12:19","slug":"cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/","title":{"rendered":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results<\/b><\/p>\n<p>OLDSMAR, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>Cryo-Cell International, Inc. (NYSE American LLC: CCEL)<\/b> (the \u201cCompany\u201d), the world\u2019s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025.<\/p>\n<p><b>Financial Results<\/b><\/p>\n<p><b><i>Revenue<\/i><\/b><\/p>\n<p>\nThe revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $43,000 in public banking revenue and $14,000 in product revenue compared to $7.97 million in processing and storage fee revenue, $41,000 in public banking revenue and $36,000 in product revenue for the second quarter of fiscal 2024.<\/p>\n<p><b><i>Net Income<\/i><\/b><\/p>\n<p>\nThe Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted common shares for the three months ended May 31, 2024.<\/p>\n<p><b><i>About Cryo-Cell International, Inc.<\/i><\/b><\/p>\n<p>\nFounded in 1989, Cryo-Cell International, Inc. is the world\u2019s first private cord blood bank. \u200eMore than 500,000 parents from 87 countries have entrusted Cryo-Cell International with \u200etheir baby\u2019s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell \u200eInternational has a public banking program in partnership with Duke University. Cryo-Cell\u2019s \u200epublic bank has provided cord blood for more than 700 transplants and operates cord \u200eblood donation sites in prominent hospitals such as Cedars\u2013Sinai Hospital in \u200eLos Angeles. Cryo-Cell\u2019s facility is FDA registered, cGMP-\/cGTP-\u200ecompliant and licensed in all states requiring licensure. Besides being AABB accredited as a \u200ecord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to \u200ereceive FACT accreditation for adhering to the most stringent cord blood quality standards \u200eset by any internationally recognized, independent accrediting organization. Cryo-Cell has \u200ethe exclusive rights \u200eto PrepaCyte-CB, the industry\u2019s most advanced cord blood processing \u200etechnology.\u200e<\/p>\n<p>\nCryo-Cell\u2019s mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available. In February 2021, Cryo-Cell entered into a license agreement with Duke University \u200ethat the Company believes has allowed Cryo-Cell to begin its transformation into an autonomous, \u200e\u200evertically \u200eintegrated cellular therapy \u200ecompany. \u200eIn March 2022, Cryo-Cell launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.extravault.com%2F&amp;esheet=54290962&amp;newsitemid=20250715194484&amp;lan=en-US&amp;anchor=www.extravault.com&amp;index=1&amp;md5=4c3275157d50014f45628c069f2f065a\">www.extravault.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release includes \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d) and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). In some cases, you can identify forward-looking statements by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cforecasts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other comparable terminology. Generally, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cplan\u201d and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.<\/p>\n<p>\nWe have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company\u2019s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company\u2019s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company\u2019s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company\u2019s business, the success of the Company\u2019s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company\u2019s ability to minimize future costs to the Company related to R&amp;D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company\u2019s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company\u2019s Form 10-Q filed on July 15, 2025.<\/p>\n<p>\nThis list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250715194484\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250715194484\/en\/<\/a><\/span><\/p>\n<p>\nIrene Smith<br \/>\n<br \/>813-749-2102<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Ismith@cryo-cell.com\">Ismith@cryo-cell.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Stem Cells Other Science Biotechnology Research Health Genetics Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250715194484\/en\/1769919\/3\/Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results OLDSMAR, Fla.&#8211;(BUSINESS WIRE)&#8211;Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the \u201cCompany\u201d), the world\u2019s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025. Financial Results Revenue The revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $43,000 in public banking revenue and $14,000 in product revenue compared to $7.97 million in processing and storage fee revenue, $41,000 in public &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-870052","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results OLDSMAR, Fla.&#8211;(BUSINESS WIRE)&#8211;Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the \u201cCompany\u201d), the world\u2019s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025. Financial Results Revenue The revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $43,000 in public banking revenue and $14,000 in product revenue compared to $7.97 million in processing and storage fee revenue, $41,000 in public &hellip; Continue reading &quot;Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T22:12:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results\",\"datePublished\":\"2025-07-15T22:12:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/\"},\"wordCount\":1004,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/\",\"name\":\"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-07-15T22:12:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk","og_description":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results OLDSMAR, Fla.&#8211;(BUSINESS WIRE)&#8211;Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the \u201cCompany\u201d), the world\u2019s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025. Financial Results Revenue The revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $43,000 in public banking revenue and $14,000 in product revenue compared to $7.97 million in processing and storage fee revenue, $41,000 in public &hellip; Continue reading \"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-15T22:12:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results","datePublished":"2025-07-15T22:12:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/"},"wordCount":1004,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/","name":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-07-15T22:12:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250715194484r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2025-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=870052"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870052\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=870052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=870052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=870052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}